Amundi Increases Position in Becton, Dickinson and Company $BDX

Amundi grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 11.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,816,703 shares of the medical instruments supplier's stock after purchasing an additional 186,541 shares during the period. Amundi owned approximately 0.66% of Becton, Dickinson and Company worth $274,922,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC grew its position in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. Northside Capital Management LLC lifted its position in shares of Becton, Dickinson and Company by 18.3% in the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier's stock worth $9,280,000 after buying an additional 9,494 shares in the last quarter. Cooke & Bieler LP boosted its stake in Becton, Dickinson and Company by 27.2% during the fourth quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier's stock valued at $218,614,000 after buying an additional 240,673 shares during the last quarter. Wealthfront Advisers LLC bought a new position in Becton, Dickinson and Company during the second quarter valued at approximately $2,567,000. Finally, Beverly Hills Private Wealth LLC purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at approximately $3,353,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $184.78 on Tuesday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $193.07. The firm has a market cap of $50.91 billion, a price-to-earnings ratio of 55.66, a PEG ratio of 13.02 and a beta of 0.21. The business's fifty day simple moving average is $170.65 and its two-hundred day simple moving average is $160.63. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts' consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 9,105 shares of company stock valued at $1,590,208. 0.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BDX. Jefferies Financial Group reaffirmed a "buy" rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Bank of America raised their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Monday, August 31st. The Goldman Sachs Group decreased their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 27th. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Finally, Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $187.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.